HER-2 amplification evaluated by fluorescence in-situ hybridization (FISH) as a predictive marker in node-positive (N+) breast cancer (BC) patients (pts) randomly treated with CMF or an anthracycline-based therapy
A. Di Leo, D. Gancberg, D. Larsimont, G. Rouas, A. Vindevoghel, C. Focan, M. Beauduin, S. Dolci, M. Paesmans, M.J. PiccartТом:
37
Рік:
2001
Мова:
english
DOI:
10.1016/s0959-8049(01)81489-1
Файл:
PDF, 164 KB
english, 2001